Logo

PYPD

PolyPid Ltd.

PYPD

PolyPid Ltd. • NASDAQ
$3.94 ▲ 3.82% (+0.14)
Market Cap $40.20 M
52w High $3.96
52w Low $2.30
Dividend Yield 0%
P/E -1.4
Volume 106.14K
Outstanding Shares 10.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.455M ▼ $-7.451M ▲ 0% $-0.37 ▲ $-7.429M ▲
Q2-2025 $0 $9.403M ▲ $-9.977M ▼ 0% $-0.78 ▼ $-9.403M ▼
Q1-2025 $0 $7.579M ▼ $-8.268M ▲ 0% $-0.7 ▲ $-7.579M ▲
Q4-2024 $0 $8.221M ▲ $-8.52M ▼ 0% $-1.13 ▲ $-8.221M ▼
Q3-2024 $0 $7.386M $-7.76M 0% $-1.22 $-7.386M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $18.975M ▼ $26.841M ▼ $11.476M ▼ $15.365M ▼
Q2-2025 $29.455M ▲ $37.687M ▲ $17.211M ▲ $20.476M ▲
Q1-2025 $8.039M ▼ $16.849M ▼ $16.763M ▼ $86K ▼
Q4-2024 $15.641M ▲ $25.22M ▲ $17.536M ▲ $7.684M ▲
Q3-2024 $9.532M $19.594M $17.436M $2.158M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2023 $-6.356M ▼ $0 $0 $0 $3.761M ▲ $0
Q3-2023 $-5.604M ▲ $0 $0 $0 $-2.051M ▲ $0
Q2-2023 $-5.837M ▲ $0 $0 $0 $-2.971M ▼ $0
Q1-2023 $-6.068M ▲ $0 ▲ $0 ▼ $0 ▲ $-2.193M ▲ $0 ▲
Q4-2022 $-6.535M $-31.555M $11.652M $-46.461M $-7.439M $-31.416M

Five-Year Company Overview

Income Statement

Income Statement PolyPid is still a classic pre‑revenue biotech: it has not yet generated product sales, so its income statement is entirely driven by research, development, and overhead costs. Losses have been steady over the past several years, though they appear to be gradually narrowing as the company manages expenses more tightly. The very large swings in per‑share loss mainly reflect capital structure changes (like the reverse split), not a sudden change in the underlying business. Overall, the income statement shows a small company funding late‑stage development rather than one with an operating business in place.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a modest base of assets, mostly in cash and related items, and very limited physical or long‑lived assets. Shareholders’ equity has been thin and at times close to break‑even, indicating that accumulated losses have largely consumed past capital. Debt has begun to appear but is still relatively small in absolute terms, so the balance sheet is not heavily leveraged, just constrained. In simple terms, this is a financially fragile, asset‑light company dependent on continued access to capital rather than one backed by substantial hard assets or retained earnings.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating spending on clinical development and overhead, with essentially no investment in big facilities or equipment in the reported period. Free cash flow mirrors operating cash flow, since capital spending is minimal. While the burn rate seems to be slowly improving, the company still relies on external financing to fund its pipeline. Management’s own disclosures suggest they believe they have runway into the medium term, but without product revenue, future raises or partner funding remain an ongoing need and a key uncertainty.

Competitive Edge

Competitive Edge PolyPid’s competitive position rests on a narrow but potentially important niche: long‑acting, locally delivered antibiotics to prevent surgical site infections. The PLEX platform, positive late‑stage data for D‑PLEX100, and favorable regulatory designations give it a differentiated profile versus traditional systemic antibiotics and standard surgical infection‑control products. In addition, in‑house sterile manufacturing is unusual for a company of this size and can be a real operational advantage. However, PolyPid is tiny compared with large medical and pharma players active around infection prevention, and it will likely depend on strong partnerships, reimbursement acceptance, and surgeon adoption to turn its scientific edge into a durable commercial foothold.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of PolyPid. The PLEX technology offers a versatile way to turn well‑known drugs into locally delivered, long‑duration therapies. D‑PLEX100 is the lead asset with late‑stage data, but the same platform is being extended into bone infections and oncology through candidates like D‑PLEX1000 and OncoPLEX. Early results in cancer models, while still preclinical, highlight the breadth of potential uses. This platform approach can create multiple shots on goal from the same core technology. The flip side is that R&D is expensive relative to the company’s size, timelines are long, and any setbacks in pivotal trials, regulatory review, or new indication development could quickly change the story, given the limited financial cushion.

Summary

PolyPid is a very small, pre‑revenue biotech with a focused but ambitious goal: using its PLEX drug‑delivery platform to improve surgical outcomes and potentially cancer treatment. Financially, it runs with lean assets, no sales, ongoing losses, and recurring cash burn, which makes it highly dependent on capital markets and partnerships. Strategically, it has notable strengths: differentiated technology, strong late‑stage data in a meaningful surgical niche, supportive regulatory designations, and a platform that can be extended into other areas. At the same time, concentration in a few programs, execution risk around regulatory approval and commercialization, and a thin balance sheet all add significant uncertainty. In essence, PolyPid combines high scientific and clinical potential with a financially constrained, high‑risk profile typical of late‑stage biotech before its first product approval.

NEWS

November 25, 2025 · 8:30 AM UTC

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Read more

November 12, 2025 · 7:30 AM UTC

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Read more

November 6, 2025 · 8:30 AM UTC

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Read more

October 29, 2025 · 8:30 AM UTC

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Read more

September 30, 2025 · 8:45 AM UTC

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Read more